Diabetes is becoming prevalent disease in globally especially in the developing world. Though there are plenty of players in the market for treating Diabetes, four major global drug companies dominate the market.

From an article on the diabetes market in China:

At present, the competition in the diabetes market is fierce. Traditional Insulin is still the most popular drug category and accounts for about half of the market. The rest is shared among GLP-1 receptor agonists (17%), DPP-4 inhibitors (21%), and SGLT2 inhibitors (6%), which are regarded as the rising stars. The current global diabetes market is mainly divided by four giant monopolies, Novo Nordisk, Sanofi, Eli Lilly, and Merck. Combined, they account for about 72% of the market.

 

Source: The Diabetes Market in China, Pharma Exec

Investors looking to profit from the growing diabetes epidemic can consider adding some the drug makers in this field. The ADR tickers of the four major players are shown below:

1. Novartis AG (NVS)

2. Eli Lilly (LLY)

3. Sanofi (SNY)

4. Merck (MRK)

Disclosure: No Positions